Skip to main content

Douglas L. Jennings, PharmD, FACC, FAHA, FCCP, FHFSA, BCPS

Headshot and logo for Talking Therapeutics with Douglas Jennings, PharmD
Talking Therapeutics
11/03/2021
This week, Dr Jennings reviews data from three recently published papers regarding what symptoms and conditions make anticoagulants a viable treatment option for patients with COVID-19.
This week, Dr Jennings reviews data from three recently published papers regarding what symptoms and conditions make anticoagulants a viable treatment option for patients with COVID-19.
This week, Dr Jennings reviews...
11/03/2021
Pharmacy Learning Network
Headshot and logo for Talking Therapeutics with Douglas Jennings, PharmD
Talking Therapeutics
08/29/2023
Dr Jennings discusses a new paper that explores the relationship between the gut microbiome and subclinical progression of atherosclerosis.
Dr Jennings discusses a new paper that explores the relationship between the gut microbiome and subclinical progression of atherosclerosis.
Dr Jennings discusses a new...
08/29/2023
Pharmacy Learning Network
Headshot and logo for Talking Therapeutics with Douglas Jennings, PharmD
Talking Therapeutics
02/09/2023
Dr Jennings shares findings from a recent trial evaluating a thiazide for patients with acute decompensated heart failure and explores which agents may be preferred options for augmenting diuresis.
Dr Jennings shares findings from a recent trial evaluating a thiazide for patients with acute decompensated heart failure and explores which agents may be preferred options for augmenting diuresis.
Dr Jennings shares findings from...
02/09/2023
Pharmacy Learning Network
Headshot and logo for Talking Therapeutics with Douglas Jennings, PharmD
Talking Therapeutics
09/15/2021
In the past, Talking Therapeutics has only covered virtual meetings, but in this week’s installment, Dr Jennings has his first in-person meeting recap.
In the past, Talking Therapeutics has only covered virtual meetings, but in this week’s installment, Dr Jennings has his first in-person meeting recap.
In the past, Talking...
09/15/2021
Pharmacy Learning Network
Headshot and logo for Talking Therapeutics with Douglas Jennings, PharmD
Talking Therapeutics
05/05/2022
Dr Jennings describes his experience taking Paxlovid after becoming infected with COVID-19 at a conference.
Dr Jennings describes his experience taking Paxlovid after becoming infected with COVID-19 at a conference.
Dr Jennings describes his...
05/05/2022
Pharmacy Learning Network
Headshot and logo for Talking Therapeutics with Douglas Jennings, PharmD
Talking Therapeutics
12/08/2022
Dr Jennings reviews a study comparing apixaban to warfarin in patients with atrial fibrillation who received hemodialysis for end-stage kidney disease.
Dr Jennings reviews a study comparing apixaban to warfarin in patients with atrial fibrillation who received hemodialysis for end-stage kidney disease.
Dr Jennings reviews a study...
12/08/2022
Pharmacy Learning Network
Jennings Headshot
Talking Therapeutics
01/10/2024
In this installment of Talking Therapeutics, Douglas Jennings highlights some of the more significant recommendations from the new 2023 atrial fibrillation treatment guidelines released by the American College of Cardiology and American Heart...
In this installment of Talking Therapeutics, Douglas Jennings highlights some of the more significant recommendations from the new 2023 atrial fibrillation treatment guidelines released by the American College of Cardiology and American Heart...
In this installment of Talking...
01/10/2024
Pharmacy Learning Network
Commentary
06/07/2021
In a past Talking Therapeutics column, Dr Jennings opined the nephroprotective effects of SGL2 inhibitors for patients with CKD. In this week’s column, he continues the kidney-focused theme with an exposé on finerenone—a novel, highly...
In a past Talking Therapeutics column, Dr Jennings opined the nephroprotective effects of SGL2 inhibitors for patients with CKD. In this week’s column, he continues the kidney-focused theme with an exposé on finerenone—a novel, highly...
In a past Talking Therapeutics...
06/07/2021
Pharmacy Learning Network
Headshot and logo for Talking Therapeutics with Douglas Jennings, PharmD
Talking Therapeutics
12/01/2021
In this week's installment of Talking Therapeutics, Dr Jennings showcases platelet-rich plasma for the treatment of musculoskeletal conditions, including its theoretical uses and efficacy data.
In this week's installment of Talking Therapeutics, Dr Jennings showcases platelet-rich plasma for the treatment of musculoskeletal conditions, including its theoretical uses and efficacy data.
In this week's installment of...
12/01/2021
Pharmacy Learning Network
Headshot and logo for Talking Therapeutics with Douglas Jennings, PharmD
Talking Therapeutics
07/28/2022
Dr Jennings reviews a new study evaluating the efficacy of COVID-19 treatments against the BA.5 variant in a laboratory setting.
Dr Jennings reviews a new study evaluating the efficacy of COVID-19 treatments against the BA.5 variant in a laboratory setting.
Dr Jennings reviews a new study...
07/28/2022
Pharmacy Learning Network